Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $63.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.41M
Average 0.43M
FBIO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Fortress Biotech, Inc.NASDAQ: FBIO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 180.1% from a year ago
Cash & equivalents stood at $255.84M at the end of Q1 FY2026, up 180.1% from a year earlier and up 222.3% from the prior quarter. Over 3 fiscal years it compounded at -23.6% a year.
Context
- Cash & equivalents amounted to 71.7% of total assets at the end of Q1 FY2026, up 20.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +180.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 79.38M USD
- Year-over-year change
- +38.6%
- 4-year CAGR
- -28.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 79.38M | +38.6% |
| FY2024 | 2024-12-31 | 57.26M | -29.2% |
| FY2023 | 2023-12-31 | 80.93M | -54.6% |
| FY2022 | 2022-12-31 | 178.27M | -41.7% |
| FY2021 | 2021-12-31 | 305.74M | — |
Cash & Equivalents vs competitors
How FBIO compares with its peers on the latest reported figures
- FBIO's Mar 2026 cash & equivalents of $255.84M is the highest of the 10 companies compared; the peer median is $50.75M.
- Its year-over-year change of +180.1% is the 3rd highest of 10, against a peer median of +35.2%.
- Cash & equivalents amounts to 71.7% of total assets for FBIO, versus a peer median of 63.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $255.84M | +180.1% | -23.6% | 71.7% | |
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $128.06M | -16.9% | +8.3% | 63.4% | |
| Mar 2026 | $115.46M | -25.9% | -7.2% | 82.6% | |
| Dec 2025 | $74.52M | -12.5% | -19.7% | 95.2% | |
| Mar 2026 | $50.75M | +76.8% | +6.9% | 28.2% | |
| Mar 2026 | $39.13M | -23.8% | -29.5% | 40.5% | |
| Mar 2026 | $16.54M | +82.3% | +41.8% | 88.3% | |
| Mar 2026 | $9.78M | +750.3% | -13.5% | 4.2% | |
| Apr 2026 | $4.01M | +35.2% | +32.1% | 58.1% | |
| Peer median (excluding FBIO) | $50.75M | +35.2% | -7.2% | 63.4% | |
Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 305.74M | 178.27M | 80.93M | 57.26M | 79.38M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 23.79M | 28.35M | 15.39M | 10.4M | 29.94M |
| Inventory | 9.86M | 14.16M | 10.21M | 14.43M | 9.62M |
| Other Current Assets | 0 | 9.66M | 10.5M | 8.28M | 5.05M |
| Total Current Assets | 346.46M | 230.43M | 117.02M | 90.37M | 123.84M |
| Property, Plant & Equipment (Net) | 34.07M | 33.01M | 23.5M | 17.12M | 14.82M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 12.55M | 27.2M | 20.29M | 31.86M | 27.61M |
| Long-term Investments | 2.22M | 2.69M | 2.44M | 1.55M | 17.66M |
| Tax Assets | (2.22M) | (2.69M) | 0 | 0 | 0 |
| Other Non-current Assets | 3.42M | 3.66M | 4.28M | 3.32M | 1.62M |
| Total Non-current Assets | 50.04M | 63.87M | 50.5M | 53.85M | 61.71M |
| Total Assets | 396.5M | 294.3M | 167.53M | 144.22M | 185.55M |
| Account Payables | 47.43M | 57.24M | 34.81M | 31.64M | 14.24M |
| Short-term Debt | 5.32M | 10.18M | 3M | 625K | 0 |
| Tax Payables | 345K | 722K | 843K | 932K | 356K |
| Deferred Revenue | 2.61M | 728K | 0 | 0 | 0 |
| Other Current Liabilities | 34.42M | 46.62M | 9.06M | 4.84M | 2.31M |
| Total Current Liabilities | 101.04M | 127.72M | 84.91M | 71.4M | 49.74M |
| Long-term Debt | 46.56M | 93.14M | 60.86M | 57.96M | 59.5M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.03M | 1.85M | 1.89M | 1.76M | 1.45M |
| Total Non-current Liabilities | 69.58M | 116.56M | 81.03M | 74.47M | 73.62M |
| Total Liabilities | 170.63M | 244.28M | 165.94M | 145.87M | 123.37M |
| Common Stock | 101K | 110K | 15K | 28K | 32K |
| Retained Earnings | (547.46M) | (634.23M) | (694.87M) | (740.87M) | (734.05M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | (103K) | 0 | 0 | 0 |
| Minority Interest | 117.2M | 8.3M | (20.96M) | (24.38M) | 12.31M |
| Total Equity | 225.88M | 50.03M | 1.59M | (1.64M) | 62.18M |
| Total Debt | 74.98M | 127.34M | 84.66M | 75.96M | 74.3M |
| Net Debt | (230.77M) | (50.92M) | 3.73M | 18.7M | (5.08M) |
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.